Published 2022 | Version v1
Publication

Exposure to natalizumab throughout pregnancy: effectiveness and safety in an Italian cohort of women with multiple sclerosis

Description

Assessing the risk of clinical and radiological reactivation during pregnancy and post partum in women with multiple sclerosis (MS) treated with natalizumab (NTZ) throughout pregnancy (LONG_EXP) compared with women interrupting treatment before (NO_EXP) and within >-30 days and ≤90 days from conception (SHORT_EXP), and describing newborns' outcomes.

Additional details

Identifiers

URL
http://hdl.handle.net/11567/1098098
URN
urn:oai:iris.unige.it:11567/1098098

Origin repository

Origin repository
UNIGE